The relationship between hormonal therapy for menopause (hormone replacement therapy, HRT) and the risk of epithelial ovarian cancer was evaluated in a collaborative re-analysis of 4 European case-control studies, 2 conducted in Greece and I each in Italy and the United Kingdom, including a total of 1,470 ovarian cancer cases and 3,271 hospital controls.
Odds ratios (ORs) for HRT use were derived after allowance for study centre, age, socio-economic level, parity, menopausal status, type of menopause, age at menopause and oral contraceptive use.
Overall, 109 (8.0%) ovarian cancer cases and 146 (4.7%) controls had ever used HRT, corresponding to an adjusted OR of 1.71 (95% confidence interval 1.30-2.25).
The point estimates of the OR were 1.77 in the first Greek study, 1.40 in the second Greek study, 1.66 in the Italian study and 1.68 in the British study.
Adjustment for possible confounders, including menopausal status, type of menopause, age at menopause and oral contraceptive use, slightly increased the OR.
Limiting the analysis to women with information on relevant aspects of HRT use revealed a weak positive association with duration and some evidence that the excess relative risk for ovarian cancer declined with time since last use.
These findings are compatible with a promoting effect of HRT in ovarian carcinogenesis. (...)
Mots-clés Pascal : Tumeur maligne, Ovaire, Facteur risque, Epidémiologie, Traitement substitutif, Hormone stéroïde, Ménopause, Europe, Etude cas témoin, Homme, Appareil génital femelle pathologie, Ovaire pathologie
Mots-clés Pascal anglais : Malignant tumor, Ovary, Risk factor, Epidemiology, Replacement therapy, Steroid hormone, Menopause, Europe, Case control study, Human, Female genital diseases, Ovarian diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 99-0166706
Code Inist : 002B20C02. Création : 16/11/1999.